OncoHost Clinches the 2026 Artificial Intelligence Excellence Award for Health Innovations OncoHost has been recognized with the 2026 Artificial Intelligence Excellence Award in the health sector for its groundbreaking AI technologies in oncology.

OncoHost Clinches the 2026 Artificial Intelligence Excellence Award for Health Innovations #United_States #CARY #OncoHost #AI_Excellence #PROphet_platform

OncoHost's New Study Bridges Serum and Plasma Proteomics for Enhanced Biomarker Discovery OncoHost's groundbreaking study highlights a new framework for integrating serum and plasma proteomic datasets, transforming biomarker research in oncology.

OncoHost's New Study Bridges Serum and Plasma Proteomics for Enhanced Biomarker Discovery #Israel #OncoHost #PROphet #Binyamina #Biomarker

OncoHost Recognized with BIG Innovation Award for Transformative Healthcare Solutions in 2026 OncoHost has received the 2026 BIG Innovation Award in the Health category, celebrating its pioneering work in precision medicine and clinical outcomes.

OncoHost Recognized with BIG Innovation Award for Transformative Healthcare Solutions in 2026 #Israel #OncoHost #PROphet #Health_Innovation #Binyamina

OncoHost Honored as Gold Winner at the 2025 Healthcare Merit Awards OncoHost has been recognized with a Gold Award at the 2025 Merit Awards for Healthcare due to its innovative proteomics platform, PROphet®.

OncoHost Honored as Gold Winner at the 2025 Healthcare Merit Awards #healthcare #Israel #OncoHost #PROphet #Binyamina

OncoHost Achieves Recognition for Innovation in Proteomics at Global BioTech Awards OncoHost, a pioneering tech firm, has been awarded 'Proteomics Innovation of the Year' by BioTech Breakthrough. This honor highlights their groundbreaking advancements in precision medicine and patient care.

OncoHost Achieves Recognition for Innovation in Proteomics at Global BioTech Awards #Israel #OncoHost #PROphet #Binyamina #BioTech_Awards

OncoHost Unveils Exciting Advances in Plasma Proteomics for NSCLC at ISLB 2025 OncoHost showcases two innovative studies on plasma proteomics for non-small cell lung cancer monitoring and prediction at ISLB 2025, highlighting a transformative approach.

OncoHost Unveils Exciting Advances in Plasma Proteomics for NSCLC at ISLB 2025 #Israel #OncoHost #NSCLC #Binyamina #PROphetNSCLC

OncoHost's PROphetNSCLC Test Now Available for Clinical Use in New York OncoHost has secured a New York State laboratory permit, enabling the use of its innovative PROphetNSCLC test, enhancing precision oncology access.

OncoHost's PROphetNSCLC Test Now Available for Clinical Use in New York #USA #New_York #OncoHost #Precision_Oncology #PROphetNSCLC

OncoHost Unveils Groundbreaking Research on Melanoma Treatment Selection at ESMO 2025 OncoHost announces exciting new research at ESMO 2025, focusing on innovative plasma proteomics for treatment selection in melanoma patients.

OncoHost Unveils Groundbreaking Research on Melanoma Treatment Selection at ESMO 2025 #None #Berlin #OncoHost #PROphet #ESMO

OncoHost Unveils Innovative Research on Small Cell Lung Cancer Subtypes at WCLC 2025 OncoHost's pivotal research on small cell lung cancer subtypes will be presented at WCLC 2025, showcasing advancements in precision medicine and patient outcomes.

OncoHost Unveils Innovative Research on Small Cell Lung Cancer Subtypes at WCLC 2025 #None #Barcelona #OncoHost #Lung_Cancer #WCLC2025

OncoHost Earns Top Recognition as Precision Oncology Leader in 2025 OncoHost has been awarded as the premier precision oncology solution for 2025 by Life Sciences Review, highlighting its innovative approach to cancer treatment.

OncoHost Earns Top Recognition as Precision Oncology Leader in 2025 #Israel #OncoHost #PROphet #Precision_Oncology #Binyamina

OncoHost Achieves Gold Winner Status at 2025 Merit Awards for R&D Excellence OncoHost has been awarded the Gold Winner status in the 2025 Merit Awards for its significant advancements in precision medicine research and development, reflecting its innovative contributions to healthcare.

OncoHost Achieves Gold Winner Status at 2025 Merit Awards for R&D Excellence #Israel #OncoHost #PROphet #Merit_Awards #Binyamina

New Study Highlights Resistance Mechanisms in Immunotherapy for Lung Cancer Patients Discover groundbreaking insights from OncoHost's study on treatment resistance in lung cancer, utilizing proteomics and AI for personalized therapy.

New Study Highlights Resistance Mechanisms in Immunotherapy for Lung Cancer Patients #Israel #Immunotherapy #OncoHost #Lung_Cancer #Binyamina

OncoHost to Present Groundbreaking Cancer Research at ASCO 2025 Event OncoHost announces that three significant research abstracts will be showcased at ASCO 2025, highlighting advances in precision medicine for various cancers.

OncoHost to Present Groundbreaking Cancer Research at ASCO 2025 Event #United_States #Chicago #Precision_Medicine #OncoHost #ASCO_2025

OncoHost Secures €2.5 Million EIC Grant to Enhance Immunotherapy Precision in Oncology OncoHost, awarded a €2.5 million grant, is set to revolutionize precision oncology. The funding will help develop a new biomarker for predicting patient response to immunotherapy.

OncoHost Secures €2.5 Million EIC Grant to Enhance Immunotherapy Precision in Oncology #Israel #Immunotherapy #Precision_Medicine #OncoHost #Binyamina

OncoHost's Innovative Plasma Proteomics Research for NSCLC Unveiled at AACR 2025 OncoHost presents groundbreaking findings on plasma proteomics and immunotherapy resistance in NSCLC at AACR 2025, enhancing personalized treatment strategies.

OncoHost's Innovative Plasma Proteomics Research for NSCLC Unveiled at AACR 2025 #USA #Chicago #OncoHost #NSCLC #AACR

OncoHost and Gustave Roussy Collaborate to Enhance Immunotherapy Safety This partnership aims to develop predictive markers for immune-related adverse events in patients receiving immunotherapy, improving patient safety and treatment outcomes.

OncoHost and Gustave Roussy Collaborate to Enhance Immunotherapy Safety #Israel #Immunotherapy #OncoHost #Binyamina #Gustave_Roussy

OncoHost Achieves Prestigious Recognition at the 2025 BIG Innovation Awards OncoHost has been awarded the 2025 BIG Innovation Award in Healthcare for its groundbreaking precision oncology solutions, including the PROphet® platform.

OncoHost Achieves Prestigious Recognition at the 2025 BIG Innovation Awards #healthcare #Israel #OncoHost #PROphet #Binyamina

OncoHost's Cary Laboratory Achieves CAP Accreditation: A Step Forward in Precision Medicine Diagnostics OncoHost has successfully achieved CAP accreditation for its Cary laboratory, showcasing its commitment to excellence in proteomic diagnostics.

OncoHost's Cary Laboratory Achieves CAP Accreditation: A Step Forward in Precision Medicine Diagnostics #USA #CARY #OncoHost #PROphet #CAP_Accreditation